Ophidion, Inc.

12:00 PM - 1:00 PM (PDT), Wednesday, June 15, 2022
Ophidion, Inc. is a private biotechnology company with a pipeline of products to treat neurodegenerative diseases using gene silencing cargoes such as siRNAs or ASOs that are complexed to a patented Trojan horse technology that is capable to deliver these various cargoes to the brain following intravenous administration. The patented technology exploits an endogenous receptor-mediated transport system to deliver small molecule drugs and biologics into the brain. This technology can deliver therapeutics for the treatment of various CNS disorders and brain malignancies. Our lead program is targeting Huntington's disease where we deliver our proprietary siRNA or ASO, complexed to our Trojan horse, to the brain following IV administration. This is highly differentiated program form relative to other competitors that deliver the cargoes via more invasive methods such as intrathecal or intracranial routes. We have other pipeline products to treat Cognitive Impairment (e.g. Alzheimer’s disease, Parkinson’s disease). The platform technology is amenable to delivering multiple classes of drugs, including small molecules and macromolecules (gene therapeutics, siRNAs, ASOs, peptides, and cDNAs). Ophidion owns ten issued patents and is prosecuting additional patents.
Speaker
photo
CEO
Ophidion, Inc.